Last edition
News about "Antibody-Drug Conjugate "
AstraZeneca, Daiichi Sankyo's Enhertu Shows Superior PFS in First-Line HER2-Mutant NSCLC
DESTINY-Lung04 results showed Enhertu delivered a median PFS of 14.3 months versus 8.3 months with pembrolizumab plus chemotherapy in first-line HER2-mutant advanced NSCLC.
Antibody-Drug Conjugate | 16/09/2026 | By News Bureau
Cipla Partners with CTTQ to Develop and Commercialise HER2-Targeted ADC in Emerging Markets
Cipla and CTTQ partner to expand access to TQB2102, an investigational HER2 bispecific ADC being evaluated across HER2-expressing cancers.
Antibody-Drug Conjugate | 01/09/2026 | By News Bureau | 108
The first patient has been dosed in the global Phase 3 TROPION-Urothelial04 trial, advancing evaluation of Datroway-based therapies for high-risk muscle-invasive urothelial cancer.
Antibody-Drug Conjugate | 27/08/2026 | By News Bureau
Akeso's B7-H3 ADC AK157D1 Cleared for Phase I Clinical Trial in China
Akeso has received NMPA clinical trial clearance for AK157D1, a next-generation B7-H3-targeting ADC, paving the way for a Phase I study in patients with advanced solid tumours in China.
Antibody-Drug Conjugate | 24/08/2026 | By News Bureau | 123
Akeso Doses First Patient in Phase 1b/2 Trial of HER3 ADC for Advanced Lung Cancer
Akeso has dosed the first patient in its Phase 1b/2 AK138D1-201 trial, assessing the HER3-targeted antibody-drug conjugate AK138D1 as monotherapy and in combination with ivonescimab for patients with advanced non-small cell lung cancer.
Antibody-Drug Conjugate | 30/07/2026 | By News Bureau | 181
AstraZeneca's investigational antibody-drug conjugate Sone-Ve demonstrated a significant overall survival benefit in the Phase 3 CLARITY-Gastric01 trial, marking a milestone in the development of targeted therapies for CLDN18.2-positive advanced gastric cancer.
Antibody-Drug Conjugate | 28/07/2026 | By News Bureau
Bio-Thera Doses First Patient in Phase 1 Trial of CD25-Targeting ADC BAT8013
Bio-Thera Solutions has dosed the first patient in a Phase 1 trial of BAT8013, a novel CD25-targeting antibody-drug conjugate designed to enhance anti-tumour immune responses in patients with advanced solid tumours.
Antibody-Drug Conjugate | 27/07/2026 | By News Bureau | 188
Glenmark Advances Global Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer
Glenmark Specialty has initiated patient enrolment in India for the Phase 3 trial of trastuzumab rezetecan, aiming to expand treatment options for patients with platinum-resistant ovarian cancer across its licensed global markets.
Antibody-Drug Conjugate | 04/07/2026 | By News Bureau | 172
The European Commission has approved Trodelvy for first-line treatment of unresectable or metastatic triple-negative breast cancer, offering a new therapeutic option for patients with one of the most aggressive forms of breast cancer.
Antibody-Drug Conjugate | 25/06/2026 | By News Bureau | 137
Zai Lab Secures China Approval for TIVDAK
Zai Lab has received China NMPA approval for TIVDAK (tisotumab vedotin), the first Antibody-Drug Conjugate (ADC) approved for previously treated recurrent or metastatic cervical cancer in China. The approval is supported by phase 3 innovaTV 301 trial data demonstrating a statistically significant overall survival benefit.
Antibody Drug Conjugate | 09/06/2026 | By News Bureau | 312
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy